Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.

Ramirez, Julio; Deck, Daniel H; Eckburg, Paul B; Curran, Marla; Das, Anita F; Kirsch, Courtney; Manley, Amy; Tzanis, Evan; McGovern, Paul C

Ramirez, Julio; Deck, Daniel H; Eckburg, Paul B; Curran, Marla; Das, Anita F; Kirsch, Courtney; Manley, Amy; Tzanis, Evan; McGovern, Paul C.

Afiliación

Ramirez J; Division of Infectious Diseases, Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
Deck DH; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Eckburg PB; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Curran M; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Das AF; AD Stats Consulting, Guerneville, California, USA.
Kirsch C; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Manley A; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Tzanis E; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
McGovern PC; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.

Open Forum Infect Dis ; 8(6): ofab135, 2021 Jun.

Article en En | MEDLINE | ID: mdl-34160474

Palabras clave

community-acquired bacterial pneumonia; moxifloxacin; omadacycline; severity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Open Forum Infect Dis Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google